Polymyositis Market Size and Growth Forecast for Businesses 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Polymyositis Market?

The polymyositis market size has shown robust growth in recent years. It is projected to expand from $1.65 billion in 2024 to $1.74 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.7%. The expansion observed in the historic period can be ascribed to improved access in developing regions, increased deployment of prednisone, the growing preference for methotrexate in symptom management, the expanding use of TNF inhibitors, and a rise in the application of antibody testing.

The polymyositis market is anticipated to experience robust expansion over the next few years. Its valuation is set to climb to $2.21 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.1%. This projected increase during the forecast period stems from factors such as the broadening use of telemedicine, the rise in remote patient monitoring, the increasing application of immunosuppressants, a surge in stem cell therapy, and the growing adoption of biosimilars. Significant trends foreseen in this period include the integration of artificial intelligence in pharmaceutical discovery, progress in targeted therapeutic approaches, the development of innovative immunomodulators, burgeoning research in regenerative medicine, and the incorporation of big data analytics.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22104&type=smp

What Are The Key Drivers Of Growth In The Polymyositis Market?

The rising occurrence of autoimmune diseases is anticipated to propel the growth of the polymyositis market in the future. Autoimmune diseases are medical conditions where the body’s immune system mistakenly attacks its own healthy cells, tissues, or organs, leading to inflammation and damage. The prevalence of these conditions is increasing because certain genetic variations can result in an overactive immune response, making individuals more prone to mistakenly attacking their own tissues. This genetic predisposition, combined with environmental factors such as infections, stress, and lifestyle choices, contributes to the growing incidence of autoimmune conditions. Polymyositis enhances the understanding of autoimmune diseases by demonstrating how immune system dysfunction leads to muscle inflammation, offering insights into underlying mechanisms and potential treatments for related conditions. For instance, in November 2024, according to Versorgungsatlas.de, a Germany-based organization, in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Consequently, the increasing prevalence of autoimmune diseases is driving the Polymyositis market.

What Are The Key Segments In The Polymyositis Market?

The polymyositismarket covered in this report is segmented –

1) By Type: Idiopathic Polymyositis; Dermatomyositis; Inclusion Body Myositis; Overlapping Myositis Syndromes

2) By Diagnosis: Physical Examination; Muscle Biopsy; Electromyography (EMG); Blood Tests; Magnetic Resonance Imaging (MRI)

3) By Treatment: Immunosuppressant; Immunoglobulins; Corticosteroids; Alkylating agents; Monoclonal Antibodies

4) By Distribution Channel: Offline; Online

5) By End User: Hospital pharmacy; Online pharmacy; Retail pharmacy

Subsegments:

1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis; Virus-Associated Polymyositis

2) By Dermatomyositis: Classic Dermatomyositis; Amyopathic Dermatomyositis; Juvenile Dermatomyositis

3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis; Hereditary Inclusion Body Myopathy

4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE); Polymyositis with Rheumatoid Arthritis (RA); Polymyositis with Systemic Sclerosis; Polymyositis with Mixed Connective Tissue Disease (MCTD)

Which Trends Are Impacting The Polymyositis Market?

Key players within the polymyositis market are actively pursuing the creation of innovative therapies, notably stem cell therapy, aiming to boost treatment effectiveness and retard the advancement of the condition. Stem cell therapy involves the application of umbilical cord-derived stem cells for regenerative medical purposes. These specific stem cells exhibit powerful immunomodulatory and anti-inflammatory attributes, establishing them as a promising choice for treating autoimmune disorders such as polymyositis. An illustrative example occurred in December 2024, when RESTEM, a US-based clinical-stage biotechnology firm, secured Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its stem cell initiative utilizing umbilical cord outer lining stem cells (ULSCs). This particular program employs umbilical cord outer lining stem cells to manage polymyositis and Dermatomyositis by fine-tuning the immune system and alleviating muscle inflammation. Early clinical evaluations have demonstrated encouraging safety and efficacy for the therapy, alongside a potential to decrease patients’ reliance on steroids.

Who Are The Top Performing Companies In The Polymyositis Market In Recent Years?

Major companies operating in the polymyositis market are Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C.H. Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Reliance Life Sciences Private Limited, ARUP Laboratories, Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, ViiV Healthcare Limited

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/polymyositis-global-market-report

What Are The Regional Market Dynamics Impacting The Polymyositis Industry?

North America was the largest region in the polymyositis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polymyositis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Polymyositis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=22104&type=smp

Browse Through More Reports Similar to the Global Polymyositis Market 2025, By The Business Research Company

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Non Steroidal Anti Inflammatory Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Anti Inflammatory Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795